Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization
NCT07288320 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization
- Lead sponsor
- Neurocrine Biosciences
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 24, 2025
- Completion date
- February 29, 2028
- Enrollment
- 150 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar i disorder, mania